keyword
MENU ▼
Read by QxMD icon Read
search

Ozurdex

keyword
https://www.readbyqxmd.com/read/28375791/intravitreal-dexamethasone-implant-for-treatment-of-serous-macular-detachment-in-central-retinal-vein-occlusion
#1
Ahmet Elbay, Hakan Ozdemir, Arif Koytak, Arif Melikov
PURPOSE: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex) treatment on serous macular detachment (SMD) in patients with nonischemic central retinal vein occlusion (CRVO). METHODS: Retrospective, interventional, noncomparative case series was conducted. Twenty-four eyes of 24 patients with macular edema (ME) and SMD secondary to nonischemic CRVO made up the study population. Patients who had received intravitreal triamcinolone and/or antivascular endothelial growth factor treatment and/or had undergone retinal photocoagulation were excluded from the study...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28360511/health-related-quality-of-life-visual-function-and-treatment-satisfaction-following-intravitreal-dexamethasone-implant-for-diabetic-macular-edema
#2
Jayashree Ramu, Irini Chatziralli, Yit Yang, Geeta Menon, Clare Bailey, Michael Eckstein, Phil Hykin, Sobha Sivaprasad
PURPOSE: The aim of this study was to explore and describe quantitatively patient-reported outcome measures (PROMs), ie, health-related quality of life (QoL), visual function and treatment satisfaction, in patients with diabetic macular edema (DME) receiving two different regimens of Ozurdex (intravitreal dexamethasone implant). METHODS: In this multicenter, prospective study, 100 patients with center-involving refractory DME were randomized 1:1 to either five monthly fixed dosing or optical coherence tomography (OCT)-guided pro re nata (PRN) regimen of dexamethasone intravitreal implant therapy...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28336283/-early-efficacy-of-dexamethasone-implant-ozurdex-%C3%A2-in-diabetic-macular-edema-real-life-study
#3
V Sarda, F Fajnkuchen, S Nghiem-Buffet, T Grenet, G Chaine, A Giocanti-Auregan
PURPOSE: To assess early efficacy of dexamethasone intravitreal implant 0.7mg (OZURDEX(®)) at the time of peak efficacy (2 months after injection) in patients with decreased visual acuity secondary to diabetic macular edema (DME). MATERIALS AND METHODS: Retrospective monocentric study. Inclusion criteria were best-corrected visual acuity (BCVA)≤70 letters (20/40) due to DME and central retinal thickness (CRT)≥300 microns (Cirrus 2, Carl Zeiss Meditec, Inc, Dublin)...
March 20, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#4
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
March 24, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28318718/-treatment-of-macular-edema-comparison-of-efficacy-and-tolerability-of-subconjunctival-triamcinolone-injections-sub-tenon-s-triamcinolone-injections-and-intravitreal-dexamethasone-implant
#5
C Carbonnière, C Couret, A Blériot, O Lebreton, H Massé, G Le Meur, P Lebranchu, M Weber
The area of uveitis is related to numerous pathological entities. One of the main causes of decreased visual acuity in these patients is macular edema. One aspect of the treatment includes cortosteroids used peri- and intra-ocularly. MATERIALS AND METHODS: The goal of our work was to estimate the criteria of efficacy (on improvement in visual acuity and macular edema, as well as time to recurrence) and safety (on intraocular pressure and cataract) of these various routes of administration of corticosteroid after a single injection...
March 16, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28237428/slow-release-dexamethasone-in-proliferative-vitreoretinopathy-a-prospective-randomized-controlled-clinical-trial
#6
Philip J Banerjee, Ana Quartilho, Catey Bunce, Wen Xing, Tapiwa M Zvobgo, Nicola Harris, David G Charteris
PURPOSE: To test the hypothesis that adjunctive slow-release dexamethasone implant (Ozurdex; Allergan Inc, Irvine, CA) can improve the outcomes of vitreoretinal surgery for established proliferative vitreoretinopathy (PVR). DESIGN: A 2-year, single-center, prospective, participant- and surgeon-masked randomized controlled clinical trial (EudraCT No. 2011-004498-96). PARTICIPANTS: A total of 140 patients requiring vitrectomy surgery with silicone oil for retinal detachment with established PVR (Grade C) were randomized to standard (control) or study treatment (adjunct) in a 1:1 allocation ratio...
February 22, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28218368/intravitreal-dexamethasone-implant-ozurdex%C3%A2-for-exudative-retinal-detachment-after-proton-beam-therapy-for-choroidal-melanoma
#7
Ariane Malclès, Anh-Minh Nguyen, Thibaud Mathis, Jean-Daniel Grange, Laurent Kodjikian
PURPOSE: To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT). METHODS: Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile...
February 8, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28196056/effect-of-an-intravitreal-dexamethasone-implant-on-diabetic-macular-edema-after-cataract-surgery
#8
Pilar Calvo, Antonio Ferreras, Fadwa Al Adel, Wantanee Dangboon, Michael H Brent
PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled...
February 10, 2017: Retina
https://www.readbyqxmd.com/read/28195619/efficacy-of-the-intravitreal-sustained-release-dexamethasone-implant-for-diabetic-macular-edema-refractory-to-anti-vascular-endothelial-growth-factor-therapy-meta-analysis-and-clinical-implications
#9
Zainab Khan, Robin K Kuriakose, Maryam Khan, Eric K Chin, David R P Almeida
BACKGROUND AND OBJECTIVE: To assess the effect on best-corrected visual acuity (BCVA) and efficacy of the intravitreal sustained-release 0.7 mg dexamethasone implant (Ozurdex; Allergan, Irvine, CA) in patients with recalcitrant diabetic macular edema (DME). PATIENTS AND METHODS: Meta-analysis utilizing the MOOSE framework and a random effects model. Studies included adults undergoing treatment with Ozurdex for DME. The methodologic quality of each study was assessed using the MINORS and the Cochrane Collaboration Risk of Bias for randomized studies...
February 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28147403/intraocular-dexamethasone-implant-as-adjunct-to-silicone-oil-tamponade-for-proliferative-vitreoretinopathy
#10
M Sherif, T J Wolfensberger
Background Proliferative vitreoretinopathy (PVR) occurs in 10 % of patients with retinal detachment and is characterized by excessive epi-, sub- or intraretinal contraction. Corticosteroids have been shown to counter this contraction. Patients and Methods Retrospective review of 5 patients (3 females, 2 males) with recurrent retinal detachment with stage C PVR. The mean age was 61.2 ± 20.5 years and myopia > - 5.0 dioptres was present in 3 eyes. Patients were treated with 23 g vitrectomy, retinectomy and endolaser, dexamethasone (Ozurdex®) injection under perfluorocarbone and 5500 cs silicone oil tamponade...
February 1, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28139100/dexamethasone-implant-with-fixed-or-individualized-regimen-in-the-treatment-of-diabetic-macular-oedema-six-month-outcomes-of-the-udbasa-study
#11
Valentina Sarao, Daniele Veritti, Claudio Furino, Ermete Giancipoli, Giovanni Alessio, Francesco Boscia, Paolo Lanzetta
PURPOSE: To evaluate a pro re nata administration of Ozurdex(®) implant versus a single administration for treating diabetic macular oedema (DME). METHODS: This exploratory study is designed as a comparative, multicentre, randomized study with a follow-up of 6 months. Patients with DME were assigned to treatment at baseline either with a single Ozurdex(®) implant during the entire six-month follow-up (fixed group) or Ozurdex(®) implant followed by retreatment on an individualized basis (PRN group)...
January 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28058154/intravitreal-dexamethasone-implant-ozurdex-for-refractory-macular-edema-secondary-to-retinitis-pigmentosa
#12
Nurgül Örnek, Kemal Örnek, İnci Elif Erbahçeci
Macular edema (ME) in retinitis pigmentosa (RP) often impairs central vision dramatically. A 41-year-old woman diagnosed with RP was referred to our outpatient clinic due to severe visual deterioration in both eyes. The patient was treated with topical carbonic anhydrase inhibitors, topical corticosteroids and intravitreal triamcinolone acetonide injections, but her ME recurred. Intravitreal 0.7 mg dexamethasone implant (Ozurdex, Allergan) was administered into both eyes without complications. On the fourth day after both injections, visual acuity improved and ME almost totally resolved...
August 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#13
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28017484/choroidal-haemangioma-and-photodynamic-therapy-anatomical-and-functional-response-of-patients-with-choroidal-hemangioma-treated-with-photodynamic-therapy
#14
O Subirà, H Brosa, D Lorenzo-Parra, L Arias-Barquet, J Català-Mora, E Cobos, P Garcia-Bru, M J Rubio-Caso, J M Caminal-Mitjana
OBJECTIVE: To study the effectiveness and limitations of photodynamic therapy (PDT) as treatment of choice in patients with symptomatic circumscribed choroidal haemangioma. METHODS: A retrospective study was conducted on 16 patients (13 men and 3 women, with mean age of 54.88 years) with circumscribed choroidal haemangioma, who attended our centre and were treated with PDT in the last 7 years. RESULTS: All patients had circumscribed choroidal haemangioma, which caused a decrease in visual acuity (VA) secondary to the presence of intraretinal microcystic oedema or neurosensory detachment...
December 22, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28012104/intravitreal-dexamethasone-implant-for-the-treatment-of-cystoid-macular-oedema-associated-with-acute-retinal-necrosis
#15
Parthopratim Dutta Majumder, Jyotirmay Biswas, Asra Ambreen, Rowayda Amin, Zahedur Rahman Pannu, Ahmed Magdy Bedda
BACKGROUND: Acute retinal necrosis is a rare but devastating ocular condition. We report two cases of acute retinal necrosis in immunocompetent patients, complicated by cystoid macular oedema and treated with intravitreal dexamethasone (OZURDEX®) implant. RESULTS: Two patients diagnosed with acute retinal necrosis were treated with intravenous acyclovir. Both of them developed cystoid macular oedema following resolution of viral retinitis. Ocular condition of the first patient was further complicated by central serous chorioretinopathy...
December 2016: Journal of Ophthalmic Inflammation and Infection
https://www.readbyqxmd.com/read/27999699/location-of-a-dexamethasone-implant-at-the-macula-after-intravitreal-injection-in-a-silicone-oil-filled-eye
#16
Cenap Mahmut Esenulku, Murat Gunay
Here, we report a case with cystoid macular edema (CME) due to central retinal vein occlusion (CRVO) presented with a dexamethasone implant (Ozurdex) trapped at the macula in her silicone oil- (SO-) filled eye after injection. No additional complications such as intraocular pressure (IOP) rise or retinal damage were observed. The CME was resolved during the follow-up period. At the last visit, 3 months following the injection, Ozurdex implant was found to be mostly dissolved without any additional ocular complications...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27957602/erratum-to-dexamethasone-intravitreal-implant-in-retinal-vein-occlusion-real-life-data-from-a-prospective-multicenter-clinical-trial
#17
Nicole Eter, Andreas Mohr, Joachim Wachtlin, Nicolas Feltgen, Andrew Shirlaw, Richard Leaback
No abstract text is available yet for this article.
January 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27926906/long-term-real-life-efficacy-and-safety-of-repeated-ozurdex%C3%A2-injections-and-factors-associated-with-macular-edema-resolution-after-retinal-vein-occlusion-the-remido-2-study
#18
MULTICENTER STUDY
Stéphan Pommier, Franck Meyer, Sébastien Guigou, Tony Barthelemy, Fréderic Gobert, Christian Hajjar, Pierre-Yves Merite, Eric Parrat, Hervé Rouhette, Fréderic Matonti
PURPOSE: The objective was to study long-term real-life efficacy and safety of repeated Ozurdex® injections and factors associated with macular edema (ME) resolution after retinal vein occlusion. METHODS: Patients with ME after retinal vein occlusion, receiving Ozurdex®, were included to assess the following endpoints: visual acuity and central retinal thickness, retreatment, number of injections, side effects and ME resolution. ME resolution was defined as permanent discontinuation of intravitreal injections (IVTs) for at least 6 months after the last IVT...
2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27915343/intravitreal-dexamethasone-implant-for-the-treatment-of-postoperative-macular-edema
#19
André Klamann, Katharina Böttcher, Philipp Ackermann, Gerd Geerling, Marc Schargus, Rainer Guthoff
INTRODUCTION: Macular edema after cataract surgery (Irvine-Gass syndrome) or pars plana vitrectomy is a postoperative complication which can lead to permanent visual loss. Increased inflammatory substances, such as prostaglandins and cytokines, are discussed to be causative. Currently, there are no evidence-based guidelines for the treatment of postoperative macular edema. Intravitreal dexamethasone (DEX) could be effective by its anti-inflammatory effect. We examined the functional and morphological results of treatment with 0...
2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27893624/prospective-evaluation-of-a-sustained-release-dexamethasone-intravitreal-implant-for-cystoid-macular-edema-in-quiescent-uveitis
#20
Rahul N Khurana, Alok S Bansal, Louis K Chang, James D Palmer, Chengqing Wu, Mark R Wieland
PURPOSE: To investigate dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the absence of intraocular inflammation. METHODS: In this prospective interventional case series, 10 patients with uveitic cystoid macular edema and quiescent uveitis were treated with dexamethasone intravitreal implant at baseline and evaluated monthly for one year. Patients were retreated whenever cystoid macular edema recurred...
November 23, 2016: Retina
keyword
keyword
33543
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"